Matthew A. Lunning
Advanced in Marginal Zone Lymphoma (MZL)

Dr. Matthew A. Lunning

Oncology | Hematology
Unmc Physicians
Emile 42nd St, 
Omaha, NE 
Accepting New Patients
Offers Telehealth
Advanced in Marginal Zone Lymphoma (MZL)
Unmc Physicians
Emile 42nd St, 
Omaha, NE 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Matthew Lunning is an Oncologist and a Hematologist in Omaha, Nebraska. Dr. Lunning is rated as an Advanced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Non-Hodgkin Lymphoma, T-Cell Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Lunning is currently accepting new patients.

His clinical research consists of co-authoring 114 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in NE
Hospital Affiliations
Bellevue Medical Center, LLC
The Nebraska Medical Center
Languages Spoken
English
American Sign Language
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 8 Less Insurance Carriers -

Locations

UNMC PHYSICIANS
Emile 42nd St, Omaha, NE 68198
Other Locations
UNMC PHYSICIANS
111 N 175th St, Omaha, NE 68118

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2025
Intervention Type: Drug, Biological, Procedure
Study Drugs: Bendamustine Hydrochloride, Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Obinutuzumab, Prednisone, Umbralisib, Vincristine Sulfate
Study Phase: Phase 2
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Intervention Type: Biological, Procedure
Study Drug: Rituximab
Study Phase: Phase 3
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Drug
Study Drugs: Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide
Study Phase: Phase 3
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Drug, Biological, Procedure
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate
Study Phase: Phase 2/Phase 3
A Multi-center Randomized Phase II Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)
A Multi-center Randomized Phase II Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: July 11, 2025
Intervention Type: Procedure, Drug
Study Drugs: Plerixafor, carmustine, etoposide, cytarabine, melphalan
Study Phase: Phase 2
A Phase 1/2 Study of Pembrolizumab Plus Pralatrexate for Treatment of Relapsed or Refractory Peripheral T-Cell Lymphomas
A Phase 1/2 Study of Pembrolizumab Plus Pralatrexate for Treatment of Relapsed or Refractory Peripheral T-Cell Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: June 26, 2025
Intervention Type: Drug, Biological
Study Drugs: Pembrolizumab, Pralatrexate
Study Phase: Phase 1/Phase 2
A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)
A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Completed
Publish Date: June 27, 2024
Intervention Type: Biological
Study Drug: JCAR017 (Lisocabtagene Maraleucel) 
Study Phase: Phase 1
Phase Ib/IIa Study of Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas
Phase Ib/IIa Study of Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas
Enrollment Status: Completed
Publish Date: April 04, 2024
Intervention Type: Drug
Study Drugs: Carfilzomib, Romidepsin, Lenalidomide
Study Phase: Phase 1/Phase 2
A Phase I/II Trial of CHOEP Chemotherapy Plus Lenalidomide as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin's Lymphoma
A Phase I/II Trial of CHOEP Chemotherapy Plus Lenalidomide as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin's Lymphoma
Enrollment Status: Completed
Publish Date: December 13, 2023
Intervention Type: Drug, Other, Procedure
Study Drugs: Cyclophosphamide, Doxorubicin, Etoposide, Lenalidomide, Prednisone, Vincristine
Study Phase: Phase 1/Phase 2
A Phase 2 Study of Venetoclax and Romidepsin With Safety Lead-In for Treatment of Relapsed/Refractory Mature T-Cell Lymphomas
A Phase 2 Study of Venetoclax and Romidepsin With Safety Lead-In for Treatment of Relapsed/Refractory Mature T-Cell Lymphomas
Enrollment Status: Completed
Publish Date: October 19, 2023
Intervention Type: Other, Drug
Study Drugs: Romidepsin, Venetoclax
Study Phase: Phase 2
A Single-Center Phase IIa Study Evaluating the Safety and Tolerability of TGR-1202 and Ibrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Trial of the Lymphoma Precision Medicine Laboratory
A Single-Center Phase IIa Study Evaluating the Safety and Tolerability of TGR-1202 and Ibrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Trial of the Lymphoma Precision Medicine Laboratory
Enrollment Status: Completed
Publish Date: October 05, 2023
Intervention Type: Drug, Other
Study Phase: Phase 2
A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-2)
A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-2)
Enrollment Status: Completed
Publish Date: August 29, 2023
Intervention Type: Drug
Study Drug: Loncastuximab tesirine
Study Phase: Phase 2
A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients With B-Cell Lymphomas
A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients With B-Cell Lymphomas
Enrollment Status: Completed
Publish Date: May 18, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias
A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias
Enrollment Status: Completed
Publish Date: November 23, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 15 Less Clinical Trials

114 Total Publications

Tumor Lysis Syndrome.
Tumor Lysis Syndrome.
Journal: The New England journal of medicine
Published: September 17, 2025
Similar Doctors
Distinguished in Marginal Zone Lymphoma (MZL)
Dr. Stefano R. Tarantolo
Hematology Oncology | Oncology | Hematology
Distinguished in Marginal Zone Lymphoma (MZL)
Dr. Stefano R. Tarantolo
Hematology Oncology | Oncology | Hematology

Oncology Hematology West, PC

7500 Mercy Rd, 
Omaha, NE 
 (3.1 miles away)
402-393-3110
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Stefano Tarantolo is a Hematologist Oncology specialist and an Oncologist in Omaha, Nebraska. Dr. Tarantolo is rated as a Distinguished provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Schnitzler Syndrome, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Tarantolo is currently accepting new patients.

Advanced in Marginal Zone Lymphoma (MZL)
Dr. Ryan Ramaekers
Hematology Oncology | Hematology | Oncology
Advanced in Marginal Zone Lymphoma (MZL)
Dr. Ryan Ramaekers
Hematology Oncology | Hematology | Oncology

Oncology Hematology West, PC

7500 Mercy Rd, 
Omaha, NE 
 (3.1 miles away)
402-393-3110
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ryan Ramaekers is a Hematologist Oncology specialist and a Hematologist in Omaha, Nebraska. Dr. Ramaekers is rated as a Distinguished provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Mantle Cell Lymphoma (MCL), Familial Colorectal Cancer, Breast Cancer, and Lung Cancer.

Advanced in Marginal Zone Lymphoma (MZL)
Dr. Robert M. Langdon
Hematology Oncology | Oncology | Hematology
Advanced in Marginal Zone Lymphoma (MZL)
Dr. Robert M. Langdon
Hematology Oncology | Oncology | Hematology

Oncology Hematology West, PC

7500 Mercy Rd, Suite 1300, 
Omaha, NE 
 (3.1 miles away)
402-393-3110
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Robert Langdon is a Hematologist Oncology specialist and an Oncologist in Omaha, Nebraska. Dr. Langdon is rated as a Distinguished provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Lung Cancer, Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Langdon is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lunning's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 21 Advanced Conditions
View All 29 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile